Optiflow in Sequential Non-Invasive Ventilation

Respiratory Failure Clinical Trial

— VNI-HD  

Official title:

Randomized Clinical Trial Comparing High Flow Oxygen Delivery System (Optiflow) With Oxygen Therapy Under High-concentration Mask on Oxygenation of Patients Who Receive Sequential Non-Invasive Ventilation (NIV) Sessions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02389166
• Other study ID #: CHUBX 2013/28
• Status: Completed
• Phase: N/A
• Start date: June 25, 2015
• Est. completion date: March 5, 2019

Study information

• Verified date: July 2019
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background : Patient with hypoxemic respiratory failure treated with NIV receive between NIV session oxygen therapy. Gaz exchange disorder with a decrease of the ratio between Partial Pressure of Arterial Oxygen (PaO2) and Inspired Fraction of Oxygen (FIO2) are noticed when NIV is stopped at the end of the session du to alveolar derecruitment Optiflow is a high flow oxygen delivery system used a heated humidifier and heated breathing circuit. In observational studies, Optiflow increase oxygenation of patients with hypoxemic respiratory failure. Oxygenation is better than under high-concentration mask and work of breathing is reduced.

The aim of the study is to compare in acute hypoxemic respiratory failure, optiflow to oxygen therapy under high-concentration mask, on patients oxygenation between NIV sessions (measured as the difference between PaO2/FiO2 ratio at the beginning and at the end of the session), during the first two NIV sessions

Study design : Prospective, randomized, controlled, multicentric, open clinical trial with two groups:

• control group with conventional clinical management, oxygen therapy and sequential used of NIV

• Optiflow group with high flow oxygen delivery system, conventional clinical management and sequential used of NIV for a period of 36 hours at least.

Number of subjects: 100 (50 patients per group) patients admitted in intensive Care Unit for hypoxemic respiratory failure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 95
• Est. completion date: March 5, 2019
• Est. primary completion date: February 5, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient at least 18 years old

• Patients affiliated to or benefiting of the French social welfare system

• Patients with ARDS on previously healthy lung. Acute respiratory insufficiency, defined as the PaO2/FIO2 ratio less than 200 mm Hg associated with the presence of lung infiltrates on chest radiograph

• Free and informed consent of patient

• Hospitalized in one of involved ICU

Exclusion Criteria:

• Existence of criteria for intubation.

• Refusal to participate in the study.

• Pregnancy

• Patient under guardianship or trusteeship

• Patients for whom a decision of non intubation has been decided.

• Patients who have received one or several NIV session for ARDS before hospital admission

• Home noninvasive ventilation

• Tracheostomy

• Hemodynamic instability

• Hypercapnia (PaCO2>45 mm Hg).

• left ventricular failure (cardiogenic pulmonary acute edema).

• Ineffective coughing.

• Recent gastric or oesophageal surgery

• Severe ventricular rhythm disorder

• High digestive haemorrhage

• Lack of collaboration

• Pernicious vomiting

• Upper airway obstruction

• Severe sepsis.

• Undrained pneumothorax.

Related Conditions & MeSH terms

• Respiratory Failure
• Respiratory Insufficiency

Intervention

Device:
• Optiflow
Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least. High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%.
• Conventional oxygen therapy
Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.

Locations

Country	Name	City	State
France	Service de Réanimation Polyvalente - CH d'Agen	Agen
France	Réanimation polyvalente - CH d'Albi	Albi
France	Service de réanimation - CH de la côte basque	Bayonne	Aquitaine
France	Service de réanimation médicale - CHU de Bordeaux	Bordeaux	Aquitaine
France	Service de Réanimation Polyvalente - CH de Libourne	Libourne	Aquitaine
France	Réanimation Polyvalente - CH de Mont de Marsan	Mont de Marsan
France	Service de Réanimation - CH de Perigueux	Perigueux	Aquitiane
France	Service de Réanimation Polyvalente - CHU de Toulouse	Toulouse	Midi-pyrenees

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average of oxygenation differences measured as the delta between PaO2/FiO2ratio at the end of the first ans second NIV session and at the end of the first and second oxygen therapy session.	Average of oxygenation differences measured as the delta between PaO2/FiO2 ratio at the end of the first NIV session and at the end of the first oxygen therapy session (according group of treatment) on the one hand and on the other hand the delta between PaO2/FiO2 ratio at the end of the second NIV session and at the end of the second oxygen thrapy session; Five measurements of PaO2/FiO2 ratio are realized with arterial blood gases: at the time of inclusion,; at the time of the end of first NIV session,; at the time of the end of first oxygen therapy session, or at the time of rescue NIV or at the time of réintubation; at the time of the end of second NIV session,; at the time of the end of second oxygen therapy session These five measurements are usually realised, and they are important to optimize patient management. The primary endpoint is based on these five measurements.	28 days
Secondary	comfort score dyspnea beetween the two NIV sessions	The comfort score and dyspnea will be assessed between the two NIV sessions	28 days
Secondary	Incidence of serious adverse events between the two NIV sessions		28 days
Secondary	Respiratory rate between the two NIV sessions	Respiratory rate to assess work of breathing between the two NIV sessions	28 days
Secondary	incidence of intubation during the NIV treatment of Acute respiratory distress syndrome (ARDS)		28 days
Secondary	ICU mortality		28 days
Secondary	28 days survival		28 days
Secondary	Hospital mortality		28 days
Secondary	ICU length of stay		28 days
Secondary	duration of mechanical ventilation		28 days